SMART Global Holdings, Inc. (SGH) Prices $3M Offering at $51/sh
Get Alerts SGH Hot Sheet
Join SI Premium – FREE
SMART Global Holdings, Inc. (Nasdaq: SGH) today announced the pricing of a proposed underwritten public offering of 3,000,000 of its ordinary shares by certain selling shareholders affiliated with Silver Lake (the “Selling Shareholders”) at a price to the public of $51.00 per share. The Company is not selling any of its ordinary shares in the offering and will not receive any of the proceeds from the sale of its ordinary shares by the Selling Shareholders.
Morgan Stanley & Co. LLC is acting as sole underwriter for the proposed offering.
The offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-227451), filed by the Company with the Securities and Exchange Commission (the “SEC”) on September 20, 2018. Before you invest, you should read the prospectus in that registration statement and the other documents the Company has filed with the SEC for more complete information about the Company and the offering. A preliminary prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and is available for free on the SEC’s website at www.sec.gov. Alternatively, copies of the prospectus supplement and the accompanying prospectus may also be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there by any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AMC Entertainment prices $200M stock offering to redeem senior notes
- CVG to join Russell 2000 and Russell 3000 indexes June 26
- Verastem reports early trial data for KRAS G12D cancer drug VS-7375
Create E-mail Alert Related Categories
Corporate News, Equity OfferingsRelated Entities
Morgan Stanley, S3Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share